• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [22721 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2001     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vagus nerve stimulation (VNS) for treatment-resistant depression
2018     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vagus nerve stimulation for chronic major depressive episodes
2018     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vagus nerve stimulation for chronic major depressive episodes
2009     HAYES, Inc. Vagus nerve stimulation for depression
2005     HAYES, Inc. Vagus nerve stimulation for depression
2013     HAYES, Inc. Vagus nerve stimulation for depression
2009     HAYES, Inc. Vagus nerve stimulation for depression
2008     Adelaide Health Technology Assessment (AHTA) Vagus nerve stimulation for epilepsy
2009     HAYES, Inc. Vagus nerve stimulation for epilepsy
2008     Medical Services Advisory Committee (MSAC) Vagus nerve stimulation for epilepsy
2003     HAYES, Inc. Vagus nerve stimulation for epilepsy
2007     HAYES, Inc. Vagus nerve stimulation for epilepsy
2014     HAYES, Inc. Vagus nerve stimulation for epilepsy
1998     Alberta Heritage Foundation for Medical Research (AHFMR) Vagus nerve stimulation for refractory epilepsy
2001     Alberta Heritage Foundation for Medical Research (AHFMR) Vagus nerve stimulation for refractory epilepsy
2006     Institute for Clinical Effectiveness and Health Policy (IECS) Vagus Nerve Stimulation for refractory epilepsy
2001     Alberta Heritage Foundation for Medical Research (AHFMR) Vagus nerve stimulation for refractory epilepsy
2004     National Institute for Clinical Excellence (NICE) Vagus nerve stimulation for refractory epilepsy in children
1998     ECRI Vagus nerve stimulation for the treatment of intractable epilepsy
2006     Blue Cross Blue Shield Association (BCBS) Vagus nerve stimulation for treatment-resistant depression
2009     National Institute for Health and Care Excellence (NICE) Vagus nerve stimulation for treatment-resistant depression
2005     Blue Cross Blue Shield Association (BCBS) Vagus nerve stimulation for treatment-resistant depression
1998     Wessex Institute for Health Research and Development (WIHRD) Vagus nerve stimulation in epilepsy
2014     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vagus nerve stimulation therapy
2015     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vagus nerve stimulation therapy
2022     Agency for Care Effectiveness (ACE) Vagus nerve stimulation with the VITARIA System for heart failure with reduced ejection fraction
2001     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vagus nerve stimulator (VNS)
2002     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Valdecoxib
2008     HAYES, Inc. Valerian for treatment of insomnia
2011     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Valganciclovir (Valcyte®) powder for oral solution
2011     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Valganciclovir (Valcyte®) tablets
2020     NIHR Health Technology Assessment programme Validation and development of models using clinical, biochemical and ultrasound markers for predicting pre-eclampsia: an individual participant data meta-analysis
2002     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Validation: dementia in elder people - primary research
2002     Centre for Clinical Effectiveness (CCE) Validity of the venous thromboembolism risk factor assessment model as described by Motykie et al (2000)
2020     Institute for Clinical and Economic Review (ICER) Valoctocogene roxaparvovec and emicizumab for hemophilia A without inhibitors: effectiveness and value
2011     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Valsartan (Diovan®)
2023     Institute for Clinical and Economic Review (ICER) Value assessment framework
2014     University of York Value based commissioning of MSK Procedures: an appraisal of the evidence for the proposed policies
1994     L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Value of echoendoscopy in gastrointestinal disease
2007     Haute Autorite de sante (HAS) Value of extra-cranial stereotactic radiotherapy
2006     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) Value of intensified nursing
2007     Haute Autorite de sante (HAS) Value of intensity-modulated radiation therapy
1999     Hannover Medical School, Medizinische Hochschule Hannover (MHH) Value of intravascular ultrasound (IVUS) in diagnostic and therapeutic heart catherisation in patients with coronary heart disease - an economic health technology assessment
2007     Haute Autorite de sante (HAS) Value of mandibular advancement devices in cases of obstructive sleep apnea-syndrome
2005     Haute Autorite de sante (HAS) Value of measuring FSH and LH levels in women aged 45 or over
2007     Haute Autorite de sante (HAS) Value of mutation detection and of the activated protein C resistance assay in inherited thrombophilia
2006     Agency for Healthcare Research and Quality (AHRQ) Value of the periodic health evaluation
2011     Agency for Healthcare Research and Quality (AHRQ) Values of older adults related to primary and secondary prevention
2019     National Institute for Health and Care Excellence (NICE) Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction. NICE interventional procedures guidance 653
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Vancomycin or metronidazole for treatment of clostridium difficile infection: clinical and economic analyses
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Vancomycin-resistant enterococci isolation and screening strategies: clinical evidence and cost-effectiveness
2015     NIHR Horizon Scanning Centre (NIHR HSC) Vandetanib (Caprelsa) for locally advanced or metastatic differentiated thyroid cancer – second line
2007     NIHR Horizon Scanning Centre (NIHR HSC) Vandetanib (Zactima, -6474, AZD-6474, ZD6474) for medullary thyroid cancer – locally advanced or metastatic
2007     NIHR Horizon Scanning Centre (NIHR HSC) Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer
2018     National Institute for Health and Care Excellence (NICE) Vandetanib for treating medullary thyroid cancer. NICE technology appraisal guidance 550
2007     National Institute for Health and Care Excellence (NICE) Varenicline for smoking cessation
2009     Penn Medicine Center for Evidence-based Practice (CEP) Varenicline for smoking cessation
2007     Quality Improvement Scotland (NHS QIS ) Varenicline for smoking cessation
2010     Canadian Agency for Drugs and Technologies in Health (CADTH) Varenicline for smoking cessation in patients with psychiatric illness: a review of the risks
2009     NIHR Health Technology Assessment programme Varenicline in the management of smoking cessation: a single technology appraisal
2001     Health Council of the Netherlands Gezondheidsraad (GR) Variant Creutzfeldt-Jakob disease and blood transfusion - review, expert panel
2014     NIHR Health Services and Delivery Research programme Variation in compulsory psychiatric inpatient admission in England: a cross-sectional, multilevel analysis
2017     NIHR Health Services and Delivery Research programme Variations in mortality across the week following emergency admission to hospital: linked retrospective observational analyses of hospital episode data in England, 2004/5 to 2013/14
2014     NIHR Health Services and Delivery Research programme Variations in outcome and costs among NHS providers for common surgical procedures: econometric analyses of routinely collected data
1996     Conseil d'Evaluation des Technologies de la Santé du Quebec (CETS) Variations in rates of tonsillectomy, adenoidectomy and myringotomy in Quebec - nonsystematic review
1993     Conseil d'Evaluation des Technologies de la Santé du Quebec (CETS) Variations in the frequency of surgical procedures by region in the province of Quebec - nonsystematic review
2020     NIHR Health Services and Delivery Research programme Variations in the organisation of Early Pregnancy Assessment Units (EPAUs) in the UK and their effects on clinical, service and patient-centred outcomes (VESPA)
2014     New Zealand National Health Committee (NHC) Varicella and rotovirus vaccination in New Zealand - assessment reports
2000     University HealthSystem Consortium (UHC) Varicella-zoster
2004     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Vascular bipolar electrocoagulation (LigaSure (TM)) and Tissular electrocoagulation and section (TissueLink (TM)) - preliminary report
2007     Institute for Clinical Effectiveness and Health Policy (IECS) Vascular endothelial growth factor inhibitors (pegaptanib, ranibizumab and bevacizumab) in age-related macular degeneration treatment
2007     Institute for Clinical Effectiveness and Health Policy (IECS) Vascular endothelial growth factor inhibitors (pegaptanib, ranibizumab and bevacizumab) in age-related macular degeneration treatment
1989     The Swedish Council on Health Technology Assessment (SBU) Vascular surgery for arteriosclerosis in the legs
2020     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Vascular-targeted photodynamic therapy with padeliporfin (Tookad® Soluble)
2013     Health Quality Ontario (HQO) Vasodilators for inhospital heart failure management: a rapid review
2015     Health Quality Ontario (HQO) Vasodilators for inhospital heart failure management: a rapid review (update)
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Vasopressin as first-line therapy for cardiac arrest: a review of the guidelines and clinical-effectiveness
2014     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Vasoprotectives: efficacy and safety of capillary stabilising agents for venous insufficiency or haemorrhoids
2003     Centre for Clinical Effectiveness (CCE) Vasospasm following subarachnoid haemorrhage: papaverine infusion, nimodipine infusion or balloon angioplasty?
2005     Adelaide Health Technology Assessment (AHTA) Vasotrac (R) continuous blood pressure monitoring
2009     HAYES, Inc. VasoView HemoPro endoscopic vein harvesting system (Maquet Cardiovascular LLC) for coronary artery bypass graft (CABG)
2012     NIHR Horizon Scanning Centre (NIHR HSC) VBLOC® vagal blocking therapy for obesity
2022     Scottish Health Technologies Group (SHTG) vCreate Neuro for the diagnosis and treatment of adults and children with epilepsy and other neurological disorders
2013     NIHR Horizon Scanning Centre (NIHR HSC) Vedolizumab for Crohn's disease – second or subsequent line
2022     National Institute for Health and Care Excellence (NICE) Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal). NICE technology appraisal guidance 826
2014     NIHR Health Technology Assessment programme Vedolizumab for treating moderate to severe active Crohn's disease after prior therapy [ID690]
2015     National Institute for Health and Care Excellence (NICE) Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy. NICE technology appraisal guidance 352
2015     National Institute for Health and Care Excellence (NICE) Vedolizumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 342
2019     Agency for Care Effectiveness (ACE) Vedolizumab for treating ulcerative colitis and Crohn's disease
2013     NIHR Horizon Scanning Centre (NIHR HSC) Vedolizumab for ulcerative colitis – second or subsequent line
2011     NIHR Horizon Scanning Centre (NIHR HSC) VEGF trap-eye (Eylea) for macular oedema secondary to central retinal vein occlusion - first line
1998     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Vein-graft surveillance - primary research
2012     HAYES, Inc. VeinViewer (Christie Digital Systems USA Inc.) for guiding venous access procedures in children
2014     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Velaglucerase alfa
2009     NIHR Horizon Scanning Centre (NIHR HSC) Velaglucerase alfa for type 1 Gaucher's disease
2010     HAYES, Inc. Velcade (Bortezomib) (Millennium: The Takeda Oncology Company) for mantle cell lymphoma
2014     NIHR Horizon Scanning Centre (NIHR HSC) Velcalcetide for secondary hyperparathyroidism – first line
2012     NIHR Horizon Scanning Centre (NIHR HSC) Velimogene aliplasmid (Allovectin) for advanced or metastatic malignant melanoma
2016     NIHR Horizon Scanning Centre (NIHR HSC) Veliparib with carboplatin and paclitaxel for early-stage triple negative breast cancer ─ neoadjuvant therapy
2010     Adelaide Health Technology Assessment (AHTA) Velscope for oral cancer screening